Eosinophilic Adenoma of the Pituitary and Carcinoid Tumor of the Rectosigmoid Area

Buse, John; Buse, Maria G.; Roberts, Walter J.

doi:10.1210/jcem-21-6-735

Cited by 24 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case of a carcinoid tumour of the duodenum associated with the pluriglandular syndrome has been reported by Fisher and Hicks (1960) and another by Gerber and Shields (1960). A rectal carcinoid in an acromegalic patient has been recorded by Buse, Buse, and Roberts (1961). It is interesting that malignant carcinoid tumours arising from the lower ileum, the commonest site of origin, do not seem to show this association.…”

Section: Necropsymentioning

confidence: 99%

The Association of Bronchial Carcinoid and Pluriglandular Adenomatosis

Williams¹,

Celestin²

1962

Thorax

110

View full text Add to dashboard Cite

Section: Necropsymentioning

confidence: 99%

The Association of Bronchial Carcinoid and Pluriglandular Adenomatosis

Williams¹,

Celestin²

1962

Thorax

110

View full text Add to dashboard Cite

“…The association of acromegaly and carcinoid tumors has also been recognized (12)(13)(14)(15)(16) and the presence of immunoreactive growth hormone (GH)I in a lung tumor has been demonstrated in one patient (15). Although ectopic production of GH could explain the presence of acromegaly, it could not be responsible for the development of a pituitary tumor.…”

Section: Introductionmentioning

confidence: 99%

Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly.

Frohman¹,

Szabó²,

Berelowitz³

et al. 1980

J. Clin. Invest.

165

View full text Add to dashboard Cite

A B S T R A C T Growth hormone (GH)-releasing activity has been detected in extracts of carcinoid and pancreatic islet tumors from three patients with GHsecreting pituitary tumors and acromegaly. Bioactivity was demonstrated in 2 N acetic acid extracts of the tumors using dispersed rat adenohypophyseal cells in primary monolayer culture and a rat anterior pituitary perifusion system. The GH-releasing effect was dose responsive and the greatest activity was present in the pancreatic islet tumor. Small amounts of activity were also found in two other tumors (carcinoid and small cell carcinoma of lung) unassociated with GH hypersecretion.Each of the tumors contained somatostatin-like immunoreactivity but the levels did not correlate with the net biologic expression of the tumor. Sephadex G-75 gel filtration indicated the GH-releasing activity to have an apparent molecular size of slightly greater than 6,000 daltons. The GH-releasing activity was adsorbed onto DEAE-cellulose at neutral pH and low ionic strength, from which it could be eluted by increasing ionic strength. The GH-releasing activity was further purified by high pressure liquid chromatography using an acetonitrile gradient on a cyanopropyl column to yield a preparation that was active at 40 ng protein/ml. Partially purified GH-releasing activity, from which most of the bioactive somatostatin had been removed, increased GH release by pituitary monolayer cultures to five times base line. Enzymatic hydrolysis studies revealed that the GH-releasing activity was resistant to carboxypeptidase, leucineaminopeptidase, and pyroglutamate-amino-peptidase but was destroyed by trypsin and chymotrypsin, inAddress reprint requests to Dr. Frohman.

show abstract

“…Other cases of ectopic GRF secretion have been associated with either presumed or proven somatotroph adenoma. These GRF-secreting tumors have included islet cell tumors of the pancreas and carcinoid tumors (1)(2)(3)(4)(5)(6)(7)(8)(9)(10).…”

Section: Grf Activity In the Tumor Mediummentioning

confidence: 99%

“…Only nine previous cases of acromegaly associated with ectopic growth hormone-releasing factor (GRF)' secretion have been reported (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). These patients have presented, with one exception (7), either with the mass effects of their extrapituitary tumors or with metastases, and the diagnoses have been made in retrospect or even at postmortem examination (2,3,8,9).…”

Section: Introductionmentioning

confidence: 99%

Somatotroph Hyperplasia

Thorner¹,

Perryman²,

Cronin³

et al. 1982

J. Clin. Invest.

360

View full text Add to dashboard Cite

A B S T R A CT A 21-yr-old woman with Turner's syndrome presented with signs and symptoms of acromegaly. The serum growth hormone (GH) (95±9.4 ng/ ml; mean±SEM) and somatomedin C (11 U/ml) levels were elevated, and an increase in GH levels after glucose instead of normal suppression, increase after thyrotropin-releasing hormone (TRH) administration instead of no change, and decrease after dopamine administration instead of stimulation were observed. The pituitary fossa volume was greater than normal (1,440 mm3) and the presence of a pituitary tumor was assumed. After tissue removal at transsphenoidal surgery, histological study revealed somatotroph hyperplasia rather than a discrete adenoma. Postoperatively, she remained clinically acromegalic and continued to show increased GH and somatomedin levels. A search was made for ectopic source of a growth hormonereleasing factor (GRF). Computer tomographic scan revealed a 5-cm Diam tumor in the tail of the pancreas. Following removal of this tumor, serum GH fell from 70 to 3 ng/ml over 2 h, and remained low for the subsequent 5 mo. Serum somatomedin C levels fell from 7.2 to normal by 6 wk postoperatively. There were no longer paradoxical GH responses to glucose, TRH, and dopamine. Both the medium that held the tumor cells at surgery and extracts of the tumor contained a peptide with GRF activity. The GRF contained in the tumor extract coeluted on Sephadex

show abstract

Eosinophilic Adenoma of the Pituitary and Carcinoid Tumor of the Rectosigmoid Area

Cited by 24 publications

References 0 publications

The Association of Bronchial Carcinoid and Pluriglandular Adenomatosis

The Association of Bronchial Carcinoid and Pluriglandular Adenomatosis

Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly.

Somatotroph Hyperplasia

Contact Info

Product

Resources

About